This report presents a strategic analysis of the US Cardiovascular Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Cardiovascular Drugs Market, offering unmatched value, accuracy and expert insights.
The United States is the world's largest economy, ahead of China. Following the COVID-19 epidemic, the country's GDP growth rate turned negative, exacerbated by rising disparities and outmoded infrastructure, which are slowing down potential GDP growth. However, the country's output recession in 2020 was less severe than that of other large advanced countries, and the country quickly recovered from the shock, with GDP already recovering to pre-pandemic levels in Q2/2021.
Healthcare in the US is more expensive than in most other countries. According to the Commonwealth Fund, the US spent approximately 17.7% of its GDP on healthcare in 2019. The second-highest-ranking country, Switzerland, spent 12.2 percent of its GDP. Surprisingly, New Zealand and Australia only devote 9.3%, or half as much as the US.
The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. Pharma revenues worldwide reached $1.42 trillion in 2021 due to the market's rapid growth over the previous two decades. With the introduction of new technology as well as more economical and effective manufacturing techniques, the pharmaceutical industry has experienced a significant transition. Additionally, the market growth has been positively driven by rising investment flow in this sector.
Critical and life-threatening diseases are more prevalent than ever in this day and age all across the world. Cardiovascular diseases are one of these serious illnesses, and their frequency has been steadily rising worldwide, thanks in large part to changes in modern lifestyle. Heart and blood vessel abnormalities, in particular, as well as potentially fatal ailments including coronary heart disease, high blood pressure, and hyperlipidemia, are included in the category of cardiovascular diseases. Conditions like myocardial infarction can be caused by cardiovascular disorders. Heart attacks and strokes, for example, Heart attacks and strokes are responsible for four out of every five fatalities from cardiovascular disease (CVD), according to the World Health Organization (WHO).
A variety of causes and trends are now driving the expansion of these drugs in the Global market for cardiovascular therapies. There is a greater understanding of the serious effects that cardiovascular disorders have on human health. Certain contemporary lifestyle trends raise the possibility that a sizable section of the population will suffer from cardiovascular disease.
The North America Cardiovascular Drug Market size is at around US $ 31.85 Bn in 2022 and is projected to reach US $ 43.40 Bn in 2030, exhibiting a CAGR of 5.4% during the forecast period.
Market Growth Drivers Analysis
The rising public awareness of cardiovascular health and the associated rise in product introductions are two major factors contributing to the growth of the US market for cardiovascular medications. Cardiovascular therapy involves a multifaceted strategy that could result in the prescription of many types of drugs. A number of significant industry leaders have released a number of cutting-edge medications that address the various therapeutic requirements for cardiovascular disorders.
Key Players
The prominent players operating in this market include Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd
1. Report Description of the US Cardiovascular Drug Market
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. US Cardiovascular Drug Market Executive Summary
2.1 US Cardiovascular Drug Market– Industry Snapshot & key buying criteria, 2021-2030
2.2 Market Size, Growth Prospects, and Key findings
3. Market Dynamics of US Cardiovascular Drug Market
3.1 Market Growth Drivers Analysis
3.2 Market Restrains Analysis
4. US Cardiovascular Drug Market Segmentation
4.1 By Drug Type
4.1.1 Cephalosporins
4.1.2 Antihypertensive
4.1.3 Antihyperlipidemic
4.1.4 Anticoagulants
4.1.5 Antiplatelet Drug
4.1.6 Other
4.2 By Disease Indication
4.2.1 Hypertension
4.2.2 Hyperlipidemia
4.2.3 Coronary Artery Disease
4.2.4 Arrhythmia
4.2.5 Others
4.3 By Distribution Channel
4.3.1 Oral
4.3.2 Intravenous
4.3.3 Others
5. US Cardiovascular Drug Market Share
5.1 Market Analysis, Insights, and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Market Players
7. Key Company Profiles
7.1 Company 1
7.1.1 Overview
7.1.2 Financial Performance
7.1.3 Product & Services
7.1.4 Strategic initiatives
7.2 Company 2
7.2.1 Overview
7.2.2 Financial Performance
7.2.3 Product & Services
7.2.4 Strategic initiatives
7.3 Company 3
7.3.1 Overview
7.3.2 Financial Performance
7.3.3 Product & Services
7.3.4 Strategic initiatives
7.4 Company 4
7.4.1 Overview
7.4.2 Financial Performance
7.4.3 Product & Services
7.4.4 Strategic initiatives
7.5 Company 5
7.5.1 Overview
7.5.2 Financial Performance
7.5.3 Product & Services
7.5.4 Strategic initiatives
8. Healthcare Policies and Regulatory Landscape
8.1 Healthcare Policies in US
8.2 Regulatory Framework in US
8.3 Pricing & Reimbursement Scenario in US Cardiovascular Drug Market
9. Factors Driving Future Growth
9.1 New Trends & Development In US Cardiovascular Drug Market
9.2 Future Opportunities
10. Strategic Recommendations
The Cardiovascular Drug Market is segmented as mentioned below:
By Drug Type (Revenue, USD Billion):
By Disease Indication (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?